16.06.2025
Wedel, Germany, 16 June 2025 – medac and Clinigen, a global specialty pharmaceutical services Group, are expanding their existing cooperation. Six key drugs produced by medac in the fields of oncology, haematology and immune-mediated diseases will be exclusively licensed and distributed by Clinigen in Australia, parts of Southeast Asia and China (APAC).
The agreement was signed last week by Frank Lucaßen, Managing Director of medac, and Jerome Charton, Chief Executive Officer of Clinigen, at Clinigen's offices in London. The new agreement strengthens Clinigen's position. The company sees significant growth opportunities in the pharmaceutical market in the APAC region, particularly in the areas of oncology, immunology and rare diseases. With an established global distribution network, regional regulatory expertise and proven market access strategies, Clinigen will be able to quickly integrate the innovative portfolio of medac.
Having already entered into a new partnership with Hyphens for the distribution of one of its key autoimmune products in Southeast Asia, medac has now sealed a new strategic collaboration by signing an exclusive marketing and distribution agreement (MDA) with the Clinigen Group.
Jerome Charton, CEO of Clinigen, said: “Building on our successful relationship with medac in APAC is a key moment for Clinigen. We are honoured by the company’s continued trust in our ability to extend the reach of these six treatments to patients in this vital region. This new agreement reinforces our shared vision to address unmet medical needs and contribute to better patient outcomes globally.”
Frank Lucaßen, CEO of medac, commented: “We have high expectations for our products in the APAC region. With Clinigen Group we have found the ideal partner to develop and accelerate patient access in these dynamic and growing markets. We are excited to start this expanded strategic relationship in order to grant patients in the region access to our critically valuable treatments and grow our business in the region substantially.”
About Clinigen
Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa, and the Asia Pacific. Clinigen has more than 1,100 employees across five continents in 15 countries and provides access in more than 130 countries every year.
For more information on Clinigen, please visit https://www.clinigen.com/